Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death
- PMID: 19934191
- PMCID: PMC2800300
- DOI: 10.1093/aje/kwp329
Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death
Abstract
To estimate the net effect of imperfectly measured highly active antiretroviral therapy on incident acquired immunodeficiency syndrome or death, the authors combined inverse probability-of-treatment-and-censoring weighted estimation of a marginal structural Cox model with regression-calibration methods. Between 1995 and 2007, 950 human immunodeficiency virus-positive men and women were followed in 2 US cohort studies. During 4,054 person-years, 374 initiated highly active antiretroviral therapy, 211 developed acquired immunodeficiency syndrome or died, and 173 dropped out. Accounting for measured confounders and determinants of dropout, the weighted hazard ratio for acquired immunodeficiency syndrome or death comparing use of highly active antiretroviral therapy in the prior 2 years with no therapy was 0.36 (95% confidence limits: 0.21, 0.61). This association was relatively constant over follow-up (P = 0.19) and stronger than crude or adjusted hazard ratios of 0.75 and 0.95, respectively. Accounting for measurement error in reported exposure using external validation data on 331 men and women provided a hazard ratio of 0.17, with bias shifted from the hazard ratio to the estimate of precision as seen by the 2.5-fold wider confidence limits (95% confidence limits: 0.06, 0.43). Marginal structural measurement-error models can simultaneously account for 3 major sources of bias in epidemiologic research: validated exposure measurement error, measured selection bias, and measured time-fixed and time-varying confounding.
Figures

Similar articles
-
Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death.Am J Epidemiol. 2012 Mar 1;175(5):381-90. doi: 10.1093/aje/kwr346. Epub 2012 Feb 1. Am J Epidemiol. 2012. PMID: 22302074 Free PMC article.
-
Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.Am J Epidemiol. 2003 Oct 1;158(7):687-94. doi: 10.1093/aje/kwg206. Am J Epidemiol. 2003. PMID: 14507605
-
Time scale and adjusted survival curves for marginal structural cox models.Am J Epidemiol. 2010 Mar 15;171(6):691-700. doi: 10.1093/aje/kwp418. Epub 2010 Feb 5. Am J Epidemiol. 2010. PMID: 20139124 Free PMC article.
-
Comparison of dynamic treatment regimes via inverse probability weighting.Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):237-42. doi: 10.1111/j.1742-7843.2006.pto_329.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16611197 Review.
-
Care of Critically Ill Patients with Human Immunodeficiency Virus.Ann Am Thorac Soc. 2020 Jun;17(6):659-669. doi: 10.1513/AnnalsATS.201909-694CME. Ann Am Thorac Soc. 2020. PMID: 32216642 Review.
Cited by
-
Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models.Am J Epidemiol. 2016 Aug 1;184(3):249-58. doi: 10.1093/aje/kww068. Epub 2016 Jul 13. Am J Epidemiol. 2016. PMID: 27416840 Free PMC article.
-
Quantitative Bias Analysis for a Misclassified Confounder: A Comparison Between Marginal Structural Models and Conditional Models for Point Treatments.Epidemiology. 2020 Nov;31(6):796-805. doi: 10.1097/EDE.0000000000001239. Epidemiology. 2020. PMID: 32826524 Free PMC article.
-
The effect of engagement in an HIV/AIDS integrated health programme on plasma HIV-1 RNA suppression among HIV-positive people who use illicit drugs: a marginal structural modelling analysis.HIV Med. 2017 Sep;18(8):580-586. doi: 10.1111/hiv.12493. Epub 2017 Mar 19. HIV Med. 2017. PMID: 28317290 Free PMC article.
-
Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART).AIDS Behav. 2015 Apr;19(4):601-11. doi: 10.1007/s10461-014-0927-4. AIDS Behav. 2015. PMID: 25342151 Free PMC article.
-
M-estimation for common epidemiological measures: introduction and applied examples.Int J Epidemiol. 2024 Feb 14;53(2):dyae030. doi: 10.1093/ije/dyae030. Int J Epidemiol. 2024. PMID: 38423105 Free PMC article.
References
-
- Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–733. - PubMed
-
- Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [see comments] N Engl J Med. 1997;337(11):734–739. - PubMed
-
- Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351(9102):543–549. - PubMed
-
- Miettinen OS. The need for randomization in the study of intended effects. Stat Med. 1983;2(2):267–271. - PubMed
-
- Greenland S, Robins JM. Identifiability, exchangeability, and epidemiological confounding. Int J Epidemiol. 1986;15(3):413–419. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI037984/AI/NIAID NIH HHS/United States
- UO1-AI-34994/AI/NIAID NIH HHS/United States
- UO1-AI-34989/AI/NIAID NIH HHS/United States
- U01 AI031834/AI/NIAID NIH HHS/United States
- UO1-AI-35042/AI/NIAID NIH HHS/United States
- UO1-AI-35040/AI/NIAID NIH HHS/United States
- U01 AI035041/AI/NIAID NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- R01-AA-017594/AA/NIAAA NIH HHS/United States
- U01 AI035043/AI/NIAID NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- U01 AI035039/AI/NIAID NIH HHS/United States
- U01 AI035042/AI/NIAID NIH HHS/United States
- UO1-HD-32632/HD/NICHD NIH HHS/United States
- UO1-AI-37984/AI/NIAID NIH HHS/United States
- U01 AI035004/AI/NIAID NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- RR024131/RR/NCRR NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- U01 AI037613/AI/NIAID NIH HHS/United States
- UO1-AI-35041/AI/NIAID NIH HHS/United States
- R03 AI071763/AI/NIAID NIH HHS/United States
- M01 RR000722/RR/NCRR NIH HHS/United States
- P30-AI-50410/AI/NIAID NIH HHS/United States
- UO1-AI-35004/AI/NIAID NIH HHS/United States
- R01 AA017594/AA/NIAAA NIH HHS/United States
- UO1-AI-34993/AI/NIAID NIH HHS/United States
- R03-AI-071763/AI/NIAID NIH HHS/United States
- UO1-AI-35039/AI/NIAID NIH HHS/United States
- UO1-AI-42590/AI/NIAID NIH HHS/United States
- U01 AI035040/AI/NIAID NIH HHS/United States
- 5-MO1-RR-00722/RR/NCRR NIH HHS/United States
- UO1-AI-31834/AI/NIAID NIH HHS/United States
- UO1-AI-35043/AI/NIAID NIH HHS/United States
- UO1-AI-37613/AI/NIAID NIH HHS/United States
- P30 AI050410/AI/NIAID NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical